Pharsight

Multaq generic

Multaq is an anti-heart failure drug owned by Sanofi Aventis Us. It contains dronedarone hydrochloride as its active ingredient. Multaq was first authorized for market use on July 1, 2009, and is available in tablet; oral dosage forms.

When will Multaq generic be available?

Multaq holds a total of 3 drug patents, none of which has expired. Therefore, the generic versions are conceivable to be released after 30 June, 2031, which is the expiration date of the last patent.

Multaq uses

Multaq has multiple uses, it can be used for the reduction in risk of hospitalization in patients with a history of paroxysmal or persistent atrial fibrillation (af) without severe heart failure and with one or more risk factors. Its administration is recommended twice a day with morning and evening meals. It is also used for the management of risk of dronedarone/beta-blocker interaction in patients in sinus rhythm with a history of paroxysmal or persistent af. Moreover, it can be used for the reduction in risk of hospitalization in patients with stable nyha class III heart failure and a history of paroxysmal or persistent af and with one or more risk factors. Lastly, it is effective in the reduction of risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors.

Multaq patent expiration

Multaq, an anti-heart failure drug, has 3 drug patents. These patents protect the drug's use for the prevention of cardiovascular hospitalization and for reducing the risk of adverse interactions between dronedarone and beta-blockers in patients suffering from atrial fibrillation. The last patent for Multaq is set to expire on June 30, 2031, after which generic versions of the drug could be released. Below are the details of the patents:

Multaq dosage

Want to ask something?